Adell A, Artigas F (2004). The somatodendritic release of dopamine in the ventral tegmental area and its regulation by afferent transmitter systems. Neurosci Biobehav Rev 28: 415–431.
Alex KD, Pehek EA (2007). Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol Ther 113: 296–320.
Artigas F, Celada P, Laruelle M, Adell A (2001). How does pindolol improve antidepressant action? TIPS 22: 224–228.
Bassi GS, Nobre MJ, Carvalho MC, Brandão ML (2007). Substance P injected into the dorsal periaqueductal gray causes anxiogenic effects similar to the long-term isolation as assessed by ultrasound vocalizations measurements. Behav Brain Res 182: 301–307.
Bert L, Rodier D, Bougault I, Allouard N, Le-Fur G, Soubrié P et al (2002). Permissive role of neurokinin NK3 receptors in NK1 receptor-mediated activation of the locus coeruleus revealed by SR 142801. Synapse 43: 62–69.
Blier P, Gobbi G, Haddjeri N, Santarelli L, Mathew G, Hen R (2004). Impact of substance P receptor antagonism on the serotonin and norepinephrine systems: relevance to the antidepressant/anxiolytic response. J Psychiatry Neurosci 29: 208–218.
Brocco M, Dekeyne A, Mannoury la Cour C, Touzard M, Girardon S, Veiga S et al (2008). Cellular and behavioural profile of the novel, selective neurokinin1 receptor antagonist, vestipitant: a comparison to other agents. Eur Neuropsychopharmacol 18: 729–750.
Brocco M, Dekeyne A, Papp M, Millan MJ (2006). Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors. Behav Pharmacol 17: 559–572.
Brocco M, Dekeyne A, Veiga S, Girardon S, Millan MJ (2002). Induction of hyperlocomotion in mice exposed to a novel environment by inhibition of serotonin reuptake a pharmacological characterization of diverse classes of antidepressant agents. Pharmacol Biochem Behav 71: 667–680.
Burghardt NS, Bush DEA, McEwen BS, LeDoux JE (2007). Acute selective serotonin reuptake inhibitors increase conditioned fear expression: blockade with a 5-HT2C receptor antagonist. Biol Psychiatry 62: 1111–1118.
Campbell BM, Merchant KM (2003). Serotonin2C receptors within the basolateral amygdala induce acute fear-like responses in an open-field environment. Brain Res 993: 1–9.
Celada P, Puig MV, Casanovas JM, Guillazo G, Artigas F (2001). Control of dorsal raphe serotonergic neurons by the medial prefrontal cortex: involvement of serotonin-1A, GABA(A), and glutamate receptors. J Neurosci 21: 9917–9929.
Chenu F, Guiard BP, Bourin M, Gardier AM (2006). Antidepressant-like activity of selective serotonin reuptake inhibitors combined with a NK1 receptor antagonist in the mouse forced swimming test. Behav Brain Res 172: 256–263.
Commons KG, Valentino RJ (2002). Cellular basis for the effects of substance P in the periaqueductal gray and dorsal raphe nucleus. J Comp Neurol 447: 82–97.
Conley RK, Cumberbatch MJ, Mason GS, Williamson DJ, Harrison T, Locker K et al (2002). Substance P (neurokinin 1) receptor antagonists enhance dorsal raphe neuronal activity. J Neurosci 22: 7730–7736.
Cremers TI, Rea K, Bosker FJ, Wikström HV, Hogg S, Mork A et al (2007). Augmentation of SSRI effects on serotonin by 5-HT2C antagonists: mechanistic studies. Neuropsychopharmacology 31: 1550–1557.
Czeh B, Fuchs E, Simon M (2006). NK1 receptor antagonists under investigation for the treatment of affective disorders. Expert Opin Investig Drugs 15: 479–486.
Dableh LJ, Yashpal K, Rochford J, Henry JL (2005). Antidepressant-like effects of neurokinin receptor antagonists in the forced swim test in the rat. Eur J Pharmacol 507: 99–105.
De Vry J, Benz U, Schreiber R, Traber J (1993). Shock-induced ultrasonic vocalization in young adult rats: a model for testing putative anti-anxiety drugs. Eur J Pharmacol 249: 331–339.
Dekeyne A, Denorme B, Monneyron S, Millan MJ (2000). Citalopram reduces social interaction in rats. This entry appears incomplete in the provided text.
